BridgeBio Study Links Acoramidis to Lower Event Risk vs Tafamidis
BridgeBio Pharma, Inc. (BBIO) reported real-world evidence from an electronic health record study of 2,684 patients with transthyretin amyloid cardiomyopathy. In the study, acoramidis was associated with an 18% lower risk of a composite outcome compared to tafamidis. Patients treated with acoramidis also experienced a 27% lower risk of cardiovascular hospitalization, a 27% lower risk of heart failure hospitalization, and a 25% lower risk of all-cause hospitalization.
The findings showed early curve separation between the treatments at approximately one month. This real-world study replicates results from prior claims data, reinforcing evidence of acoramidis differentiating itself from established competitor tafamidis in clinical settings. Lower hospitalization rates highlight potential clinical advantages and cost savings for healthcare providers.
Key factors to monitor moving forward include peer-reviewed publication of the full data, longer-term follow-up including mortality outcomes, shifts in insurance payer coverage policies, and evidence of large-scale physician switching to acoramidis.
Key points
- Acoramidis was associated with an 18% lower risk of a composite outcome versus tafamidis in 2,684 patients.
- Hospitalization risks were 25% to 27% lower for acoramidis across heart failure, cardiovascular, and all-cause admissions.
- Treatment curves separated early at approximately one month, indicating rapid differences in outcomes.
- Results replicate previous claims research, building additional consistency across real-world datasets.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were the key findings of the BridgeBio acoramidis study?
In a study of 2,684 ATTR-CM patients, acoramidis was linked to an 18% lower risk of a composite outcome and a 25% to 27% reduction in hospitalizations compared to tafamidis.
How quickly did acoramidis demonstrate outcome differences?
The real-world data showed separation in clinical outcome curves at around one month of treatment.
What should investors watch next for BridgeBio's drug?
Important next steps include peer-reviewed publication, longer follow-up with mortality data, updates to payer policies, and real-world physician adoption.